Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Molecules ; 27(10)2022 May 18.
Article in English | MEDLINE | ID: covidwho-1953750

ABSTRACT

Voltage-gated potassium channels of the Kv1.3 type are considered a potential new molecular target in several pathologies, including some cancer disorders and COVID-19. Lipophilic non-toxic organic inhibitors of Kv1.3 channels, such as statins and flavonoids, may have clinical applications in supporting the therapy of some cancer diseases, such as breast, pancreas, and lung cancer; melanoma; or chronic lymphocytic leukemia. This study focuses on the influence of the co-application of statins-simvastatin (SIM) or mevastatin (MEV)-with flavonoids 8-prenylnaringenin (8-PN), 6-prenylnarigenin (6-PN), xanthohumol (XANT), acacetin (ACAC), or chrysin on the activity of Kv1.3 channels, viability, and the apoptosis of cancer cells in the human T cell line Jurkat. We showed that the inhibitory effect of co-application of the statins with flavonoids was significantly more potent than the effects exerted by each compound applied alone. Combinations of simvastatin with chrysin, as well as mevastatin with 8-prenylnaringenin, seem to be the most promising. We also found that these results correlate with an increased ability of the statin-flavonoid combination to reduce viability and induce apoptosis in cancer cells compared to single compounds. Our findings suggest that the co-application of statins and flavonoids at low concentrations may increase the effectiveness and safety of cancer therapy. Thus, the simultaneous application of statins and flavonoids may be a new and promising anticancer strategy.


Subject(s)
COVID-19 , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Neoplasms , Apoptosis , Cell Line , Flavonoids/pharmacology , Flavonoids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Kv1.3 Potassium Channel/metabolism , Neoplasms/drug therapy , Simvastatin/pharmacology
2.
Drug Discov Ther ; 14(3): 143-144, 2020 Jul 15.
Article in English | MEDLINE | ID: covidwho-612733

ABSTRACT

In the midst of a pandemic, finding effective treatments for coronavirus disease 2019 (COVID-19) is the urgent issue. In "chronic inflammatory diseases", the overexpression of delayed rectifier K+-channels (Kv1.3) in leukocytes is responsible for the overactivation of cellular immunity and the subsequent cytokine storm. In our previous basic studies, drugs including chloroquine and azithromycin strongly suppressed the channel activity and pro-inflammatory cytokine production from lymphocytes. These findings suggest a novel pharmacological mechanism by which chloroquine, with or without azithromycin, is effective for severe cases of COVID-19, in which the overactivation of cellular immunity and the subsequent cytokine storm are responsible for the pathogenesis.


Subject(s)
Betacoronavirus , Coronavirus Infections/drug therapy , Cytokines/antagonists & inhibitors , Drug Delivery Systems/methods , Kv1.3 Potassium Channel/antagonists & inhibitors , Lymphocytes/drug effects , Pneumonia, Viral/drug therapy , Azithromycin/administration & dosage , COVID-19 , Chloroquine/administration & dosage , Coronavirus Infections/metabolism , Cytokines/metabolism , Drug Delivery Systems/trends , Humans , Kv1.3 Potassium Channel/metabolism , Lymphocytes/metabolism , Pandemics , Pneumonia, Viral/metabolism , SARS-CoV-2 , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL